Characteristic | Number of patients (%) | |
---|---|---|
Remifentanil (n = 57) | Comparator (n = 48) | |
Any adverse event | 19 (33) | 16 (33) |
Any drug-related adverse event | 6 (11) | 4 (8) |
Any serious adverse event | 7 (12) | 6 (13) |
Any drug-related serious adverse event | 0 (0) | 1 (2) |
Premature discontinuation from the study | 12 (21) | 10 (21) |
Deaths | 7 (13) | 5 (10) |
Re-intubated within 10 daysa | 7 (25) | 2 (12) |
Most commonly occurring adverse events (≥ 5%) | ||
Hypotension | 3 (5) | 4 (8) |
Atrial fibrillation | 4 (7) | 2 (4) |
Vomiting | 3 (5) | 0 (0) |
Septic shock | 0 (0) | 3 (6) |